A review of gut microbiota and Parkinson’s disease

doi:10.3868/j.issn.2096-0689.2018.04.003

Journal of Translational Neuroscience

2018, Vol. 3

Issue (4) : 21-28 https://doi.org/10.3868/j.issn.2096-0689.2018.04.003

Review

A review of gut microbiota and Parkinson’s disease

Fengxian Chen¹, Qinyong Ye^1,2*

1.Department of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, Fuzhou 350001, China
2.Key Laboratory of Brain Aging and Neurodegenerative Diseases, Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou 350001, China

Download: PDF(10337 KB)
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract In Parkinson’s disease (PD), the alpha-synuclein (α-syn) pathology occurs both in the enteric nervous system (ENS) and parasympathetic nerves in the early stage of PD, which precedes the central nervous system (CNS) pathology and is related to gastrointestinal dysfunction precedes the onset of motor symptoms in PD. Studies have shown that gut microbiota can affect brain activity through the microbiota-gut-brain axis in PD patients. They can promote the development of PD and might be the origin of PD. There are four communication routes between gut microbiota and brain, which respectively are the gut-brain’s neural network, endocrine system, gut immune system, and barrier paths which include intestinal mucosal barrier and blood-brain barrier (BBB). Based on the alteration of fecal microbiota composition in PD, it is worthwhile to investigate whether microbiota analysis could be used as a biomarker for premotor PD. As a potential therapy, fecal microbiota transplantation (FMT) may be a promising treatment for PD patients. Further studies are needed to elucidate the causal relationship between gut microbiota and PD.

Keywords Parkinson’s disease (PD) gut microbiota gut microbiota-gut-brain axis

Issue Date: 15 December 2018

Cite this article:

Fengxian Chen, Qinyong Ye. A review of gut microbiota and Parkinson’s disease[J]. Journal of Translational Neuroscience,2018, 3(4): 21-28.

URL:

https://academic.hep.com.cn/jtn/EN/10.3868/j.issn.2096-0689.2018.04.003
https://academic.hep.com.cn/jtn/EN/Y2018/V3/I4/21

[1]	Wei Li, Xiaohan Yu, Shun Yu, . Parkinson’s disease: how should we consider the selectivity and progressivity of its neuropathology?[J]. Journal of Translational Neuroscience, 2019, 4(3): 24-36.
[2]	Qihan Song, Wenjiao Yu, Shun Yu, . Alpha-synuclein in body fluids as a diagnostic biomarker for Parkinson’s disease[J]. Journal of Translational Neuroscience, 2019, 4(3): 14-23.
[3]	Hanjiang Luo, Min Chen, Shun Yu, . Pathogenic roles of alpha-synuclein in Parkinson’s disease and multiple system atrophy[J]. Journal of Translational Neuroscience, 2019, 4(3): 1-13.
[4]	Ge Gao, Hui Yang. Brain insulin resistance and Parkinson’s disease[J]. Journal of Translational Neuroscience, 2018, 3(4): 29-37.
[5]	Ting Zhang, Ke Wang, Limin Liu, Wei Wang, Li Zhang, Jun Jia, Xiaoli Gong, Xiaomin Wang. Function and mechanism of traditional Chinese medicine in the prevention and treatment of Parkinson’s disease[J]. Journal of Translational Neuroscience, 2017, 2(4): 12-23.

Viewed

Full text

Abstract

Cited

Shared

Discussed